Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]

Anrukinzumab was developed by Wyeth.

References

  1. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
Allikas: http://en.wikipedia.org/wiki/Anrukinzumab
No tags for this post.